First of all, thank you for your continued readership of ONCOLOGY: Perspectives on Best Practices
Dear Readers,
First of all, thank you for your continued readership of ONCOLOGY: Perspectives on Best Practices. In celebration of the 25th year of our existence, we've dedicated this special issue to a discussion of some of the most important progress that has been made in oncology over the journal's lifetime.
To lend coherence to the issue and provide context for the articles you see, we'd like to take a moment to describe what we've included and why. The issue starts with a revisiting of the 2002 article Chronic Inflammation and Cancer, originally by Emily Shacter and Sigmund Weitzman (here joined by David Kamp). This has been ONCOLOGY's all-time top-cited article, and although published nearly 10 years ago, the appropriateness of a revision of this manuscript reflects the continued, strong interest in this topic.
Next, we've asked ONCOLOGY's Editors-in-Chief to look back over the past quarter-century in their respective subspecialties and give us a sense of what has been accomplished and where the next challenges lie. Nancy Davidson writes on the field of medical oncology, Bill Wood gives his perspective on changes in surgical oncology, Nora Janjan discusses radiation oncology, and Jim Armitage provides his thoughts on the past and present of hematologic oncology.
Finally in this issue, we've asked the authors of four other top-cited articles to revisit their original papers and provide a brief overview of interesting developments that have occurred since their articles' publication. As you know, many of the issues that oncologists have dealt with in the past are still with us, although progress has been made; we hope you find the updates useful.
We would also like to draw your attention to our newly revised editorial board. We've restructured the board to reflect our continued interest in serving the daily needs of the practicing oncologist, adding a subsection of community oncologists to represent their interests, and inviting some rising stars in various subdisciplines to make sure we capture what's up and coming across the many and diverse areas in oncology.
We hope you enjoy this issue and, as always, we welcome your feedback on ONCOLOGY: Perspectives on Best Practices and the cancernetwork.com.
Best wishes,
Rachel Warren
Editorial Director
rachel.warren@ubm.com
Susan Beck
Executive Editor
susan.beck@ubm.com
Efficacy and Safety of Zolbetuximab in Gastric Cancer
Zolbetuximab’s targeted action, combined with manageable adverse effects, positions it as a promising therapy for advanced gastric cancer.
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.